Wednesday, March 25, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Baird Analyst Upgrades Thor Industries with Outperform Rating and Increased Price Target

Elaine Mendonca by Elaine Mendonca
March 7, 2024
in Breaking News
0
Automotive Stock Market Today
0
SHARES
9
VIEWS
Share on FacebookShare on Twitter

Baird analyst Craig Kennison remains bullish on Thor Industries (NYSE: THO), giving it an Outperform rating and increasing the price target to $120 from $115. The revised target signifies Kennison’s optimistic view on the company’s future prospects and its ability to capitalize on market opportunities.

Thor Industries Inc. (THO) Stock Price Drops 15.44% but Shows Signs of Recovery in Pre-Market Trading

On March 7, 2024, Thor Industries Inc. (THO) experienced a significant drop in its stock price, closing at $107.04, a decrease of $19.55 or 15.44% from the previous market close. Despite the steep decline in price, there was a glimmer of hope for THO investors as the stock showed signs of recovery in pre-market trading. The stock rose by $0.81, indicating a potential rebound from the previous day’s losses. It is important for investors to closely monitor THO’s stock performance in the coming days to see if this uptick in pre-market trading continues and if the stock is able to regain some of its lost value. Analysts will be watching closely to see if THO can sustain this momentum and potentially recover from the recent drop in price.

THO Stock Performance Declines on March 7, 2024: Revenue, Net Income, and EPS Plummet

On March 7, 2024, THO stock experienced a decline in its performance based on the financial data provided by CNN Money. The company’s total revenue for the past year was reported at $11.12 billion, which decreased by 31.82% compared to the previous year. In the second quarter of the fiscal year, the total revenue dropped even further to $2.21 billion, marking an 11.72% decrease from the previous quarter.

Similarly, THO’s net income also saw a significant decrease in both the yearly and quarterly comparisons. The net income for the past year was $374.27 million, showing a 67.11% decrease from the previous year. In the second quarter, the net income plummeted to $7.22 million, indicating an 86.53% decrease from the previous quarter.

Earnings per share (EPS) followed the same downward trend as total revenue and net income. The EPS for the past year was $6.95, which decreased by 66.25% compared to the previous year. In the second quarter, the EPS dropped to $0.13, marking an 86.48% decrease from the previous quarter.

Overall, the financial performance of THO on March 7, 2024, reflected a decline in revenue, net income, and earnings per share. Investors and analysts may view these numbers as a cause for concern, as they indicate a downward trajectory in the company’s financial health. It will be important for THO to address the factors contributing to these declines and implement strategies to improve its financial performance in the upcoming quarters.

Tags: THO
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Finance_ Chart Down

Anticipated Strong Financial Performance for Superior Corporation in Fiscal Year 2024

Retail Market Capitalization

Anticipated Boost in Comparable Sales for Big Lots in First Quarter of Fiscal 2024

Biotechnology Stock Bull Market

Groundbreaking Licensing Agreement to Develop RNAi Therapy for FSHD

Recommended

BigBearai Holdings Stock

BigBear.ai Faces Critical Test as Revenue Plummets and Losses Mount

6 months ago
D-Wave Quantum Stock

D-Wave Quantum: CFO’s Multi-Million Dollar Exit Amidst Major Capital Raise

4 months ago
Brightcove Stock

Bending Spoons Forges AI-Powered Streaming Future with Brightcove at the Core

6 months ago
Microsoft Stock

Microsoft Faces Critical Earnings Test Amid AI Expectations

5 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Regulatory Rebuke Sends ImmunityBio Shares Tumbling

Realty Income’s Strategic Financing Defies High Interest Rate Environment

IBM Shares Face Pressure from Analyst Downgrades and Acquisition Concerns

Battalion Oil Navigates Debt and Operational Overhaul

Divergent Analyst Views Highlight Coeur Mining’s Strategic Transition

Rocket Lab Stock Attracts Bullish Analyst Sentiment Amid Growth Trajectory

Trending

Bionxt Solutions Stock
Healthcare

BioNxt Solutions Enters Pivotal Commercial Phase with Key Patents

by SiterGedge
March 25, 2026
0

BioNxt Solutions has formally initiated the commercial phase for its sublingual drug delivery platform, marking a significant...

Take-Two Stock

GTA VI Launch Date Sets Stage for Take-Two’s Financial Horizon

March 25, 2026
Ocugen Stock

Ocugen Shares Slide Despite Positive Clinical Trial Results

March 25, 2026
ImmunityBio Stock

Regulatory Rebuke Sends ImmunityBio Shares Tumbling

March 25, 2026
Realty Income Stock

Realty Income’s Strategic Financing Defies High Interest Rate Environment

March 25, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • BioNxt Solutions Enters Pivotal Commercial Phase with Key Patents
  • GTA VI Launch Date Sets Stage for Take-Two’s Financial Horizon
  • Ocugen Shares Slide Despite Positive Clinical Trial Results

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com